Search for a state or federal candidate to see the donors and industries that support them. Ballot measures allow voters to vote directly on a law or policy change. Explore the ballot measures ...

Against this backdrop, Cubist is investing $400 million this year in antibiotic R&D. Cubist extends superbug R&D to Europe | pharmaphorum Skip to main content ...

Investment analysts at HC Wainwright cut their FY2028 earnings estimates for shares of Milestone Pharmaceuticals in a report issued on Monday, March 17th. HC Wainwright analyst P. Trucchio now expects ...

In early 2001, it had also in-licensed European rights to Cidecin, an injectable anti-infective from Cubist Pharmaceuticals in Lexington, Massachusetts. But what Gilead really needed, management ...